Literature DB >> 8318508

Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a).

P Lesnik1, A Vonica, M Guérin, M Moreau, M J Chapman.   

Abstract

Human plasma contains a multivalent, Kunitz-type proteinase inhibitor termed tissue factor pathway inhibitor (TFPI), which specifically inhibits the action of the factor VII(a)-tissue factor complex in coagulation. In the present study, we examined the distribution and anticoagulant activity of TFPI among plasma lipoprotein subspecies separated by isopycnic density gradient ultracentrifugation; this procedure permitted the simultaneous fractionation of the major lipoprotein classes (very-low-density lipoprotein [VLDL], intermediate-density lipoprotein [IDL], low-density lipoprotein [LDL], high-density lipoprotein [HDL] 2 and 3, and very-high-density lipoprotein [VHDL]). Studies of eight normolipidemic subjects revealed two major lipoprotein carriers of TFPI activity: dense LDL subspecies (d = 1.039 to 1.063 g/mL) and both dense HDL particles and VHDL (d = 1.133 to 1.190 g/mL), representing 33.8% and 35.9%, respectively, of the total lipoprotein-associated TFPI activity in plasma. TFPI activity was also associated with lipoprotein(a) (Lp[a]), whose density distribution (d = 1.044 to 1.100 g/mL) overlapped that of LDL and HDL2; such association was related to Lp(a)'s particle size and phenotype. VLDL, IDL, and LDL1 through LDL3 (d = 1.019 to 1.039 g/mL), HDL2 (d = 1.063 to 1.100 g/mL), and light subfractions of HDL3 (d = 1.100 to 1.167 g/mL) conveyed only 1.8%, 10%, and 18.5%, respectively, of lipoprotein-associated TFPI activity. Such anticoagulant activity was dependent on the presence of TFPI protein. The dense subspecies of HDL3 (d = 1.133 to 1.167 g/mL) with which TFPI was preferentially associated were small, displayed a cholesteryl ester to protein ratio of approximately 0.2, and were deficient in phospholipid (13.6% to 18.3%). HDL subspecies of d = 1.110 to 1.167 g/mL mainly contained the higher relative molecular mass form of TFPI of 41 kD (a form that is known to be covalently associated with apolipoprotein [apo] A-II) and minor bands of the 35- and 52-kD forms. The second major localization of TFPI was within the hydrated density range of small, dense LDL particles (d = 1.033 to 1.063 g/mL), which in comparison with light LDL (d = 1.019 to 1.033 g/mL) exhibited a markedly lower proportion of triglyceride and enrichment in cholesteryl ester.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318508     DOI: 10.1161/01.atv.13.7.1066

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  10 in total

1.  TFPIβ is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes.

Authors:  Thomas J Girard; Elodee Tuley; George J Broze
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

Review 2.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Expression and characterization of wild-type TFPI and the [P151L]TFPI mutant in insect cells.

Authors:  Elmar Thyzel; Sabine Siegling; Thomas Brinkmann; Knut Kleesiek; Christian Götting
Journal:  Mol Cell Biochem       Date:  2006-02       Impact factor: 3.396

4.  The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va.

Authors:  M Ndonwi; T J Girard; G J Broze
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

Review 5.  Tissue factor pathway inhibitor: structure-function.

Authors:  George J Broze; Thomas J Girard
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

Review 6.  Tissue factor pathway inhibitor as a multifunctional mediator of vascular structure.

Authors:  Eric W Holroyd; Thomas A White; Shuchong Pan; Robert D Simari
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

7.  Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well?

Authors:  Gianluca Petrillo; Plinio Cirillo; Greta-Luana D'Ascoli; Fabio Maresca; Francesca Ziviello; Massimo Chiariello
Journal:  Curr Cardiol Rev       Date:  2010-11

Review 8.  Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium.

Authors:  Giuseppe D Norata; Alberico L Catapano
Journal:  Vasc Health Risk Manag       Date:  2005

9.  Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates.

Authors:  Ahmed Kouta; Debra Hoppensteadt; Emily Bontekoe; Walter Jeske; Richard Duff; Lee Cera; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

10.  Consistent high concentration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients--evidence of non-exosomal transport.

Authors:  Claire Gourzones; François-Régis Ferrand; Corinne Amiel; Benjamin Vérillaud; Ana Barat; Maryse Guérin; Charles-Henry Gattolliat; Aurore Gelin; Jihène Klibi; Arij Ben Chaaben; Véronique Schneider; Fethi Guemira; Joël Guigay; Philippe Lang; Anne-Sophie Jimenez-Pailhes; Pierre Busson
Journal:  Virol J       Date:  2013-04-16       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.